

In-Common Laboratories

Head Office: 57 Gervais Drive North York, Ontario M3C 1Z2

(416) 422-3000

Toll Free: (888) 285-7817

www.ICLabs.ca

Bennett, Emily, ND Bennett, Emily, ND 464 King St W

Hamilton, ON L8P 1B7

Canada

Patient Name Sex Date of Birth (mm/dd/yyyy)

Tigchelaar, 04/01/1982 M

Alex

Client's File No. Order ID

36016279

Report Printed

ICL Login Date (mm/dd/yyyy)

10/05/2016 11:11AM

Health Number

Authorized Requester Bennett, Emily, ND

Organic Acids Sample ID: ICL161005026

Final - Approved 10/24/2016 6:10PM

Collection Date (mm/dd/yyyy)

11/11/2016 10:57AM

10/03/2016 9:00AM

Order Choice Testing Site: The Great Plains Laboratory, 11813 W 77th St, Lenexa KS 66214

Comments:

TEST RESULT FLAG NORMAL/THERAPEUTIC UNITS TEST SITE

RANGE

Attached Attachment ICL1

Reporting Laboratories:

(1) ICL1, Non-Interfaced Test Site,

Patient Complete Name: Tigchelaar, Alex

Order ID: 36016279 Current Page Number: 1

Total Pages Count: 1



William Shaw, Ph.D., Director

11813 West 77th Street, Lenexa, KS 66214

(913) 341-8949

Fax (913) 341-6207

Requisition #:

463629

Physician:

IN COMMON LABORATORIES

Patient Name:

Alex Tigchelaar 36016279

Date of Collection:

10/3/2016

Patient Age: Patient Sex: 34

Time of Collection:

09:00 AM

Print Date:

10/20/2016



Organic Acids Test - Nutritional and Metabolic Profile

Metabolic Markers in Urine

Reference Range (mmol/mol creatinine) **Patient** Value

Reference Population - Males Age 13 and Over

Intestinal Microbial Overgrowth

Vacat	and	Eunaa	l Markers
reasi	anu	runua	LIVIALKEIS

	t and Fungal Markers							
1	Citramalic	0.11	2.0	0.41	0.4			
2	5-Hydroxymethyl-2-furoic	5	18	0	(0)			
3	3-Oxoglutaric	5	0.11	0	000			
4	Furan-2,5-dicarboxylic	5	13	0.17	(0.1)			
5	Furancarbonylglycine	<u> </u>	2.3	0	0.00			
6	Tartaric	≤	5.3	0.12	0.12			
7	Arabinose	5	20	15	15			
8	Carboxycitric	5	20	0.86	0.86			
9	Tricarballylic	5	0.58	0.10	0.10			
Bacte	Bacterial Markers							
10	Hippuric	5	241	205	205			
11	2-Hydroxyphenylacetic	0.03	0.47	0.17				
					4.17			
12	4-Hydroxybenzoic	0.01	0.73	0.11	0.1			
12 13	4-Hydroxybenzoic 4-Hydroxyhippuric	0.01		0.11	· ·			
		\$			0.11			
13 14	4-Hydroxyhippuric DHPPA (Beneficial Bacteria)	\$	14	1.1	1.1			
13 14 Clost 15	4-Hydroxyhippuric	<u> </u>	14 0.23	1.1	1.1			
13 14 Clost 15 (C. dif	4-Hydroxyhippuric DHPPA (Beneficial Bacteria) ridia Bacterial Markers 4-Hydroxyphenylacetic	≤ ≤ ≤ ≤ ≤	14 0.23	1.1 0.06	(1.1)			
13 14 Clost 15 (C. diff	4-Hydroxyhippuric DHPPA (Beneficial Bacteria) ridia Bacterial Markers 4-Hydroxyphenylacetic fficile, C. stricklandii, C. lituseburense & others HPHPA porogenes, C. caloritolerans, C. botulinum & others 4-Cresol	≤ ≤ ≤ ≤ ≤	14 0.23 18 102	1.1 0.06 5.1	(0.1) (0.1) (0.0)			

	isition #: 463629			Physician:	IN COMMON LABORATORIES
Patient Name: Alex Tigchelaar 36016279			Date of Collection:	10/3/2016	
/leta	bolic Markers in Urine	Reference Range mmol/mol creatinine)	Patient Value	Reference F	Population - Males Age 13 and Over
O	calate Metabolites				
19	Glyceric	0.21 - 4.9	0.94	0.94	
20	Glycolic	18 - 81	L 9.6	9.6	
21	Oxalic	8.9 - 67	47		47
GI	ycolytic Cycle Metabolites				
22	Lactic	0.74 - 19	2.8	2.8	
23	Pyruvic	0.28 - 6.7	1.4	1.4	
Mi	tochondrial Markers - Krel	os Cycle Metabolites			
24	Succinic	≤ 5.3	3.3	10	3.3
25	Fumaric	≤ 0.49	0.06	0.06	
26	Malic	≤ 1.1	0.09	0.09	
27	2-Oxoglutaric	≤ 18	5.9		5.9
28	Aconitic	4.1 - 23	L 2.8	2.8	
29	Citric	2.2 - 260	47	47	
M	itochondrial Markers - Am	ino Acid Metabolites	;		
30	3-Methylglutaric	0.02 - 0.38	0.27		(£27)
31	3-Hydroxyglutaric	≤ 4.6	1.5		.5
32	3-Methylglutaconic	0.38 - 2.0	0.86	0.86	
Ne	eurotransmitter Metabolites	5			
	nylalanine and Tyrosine Metabolit	es			
Pher	,	0.39 - 2.2	0.89	0.89	
33	Homovanillic (HVA) amine)				
33 (dopa 34	Homovanillic (HVA)	0.53 - 2.2	0.94	0.94	
33 (dopa 34 (nore	Homovanillic (HVA) amine) Vanillylmandelic (VMA)	0.53 - 2.2 0.32 - 1.4	0.94 0.95	0.90	0.95
33 (dopa 34 (nore 35	Homovanillic (HVA) amine) VanillyImandelic (VMA) pinephrine, epinephrine) HVA / VMA Ratio tophan Metabolites	0.32 - 1.4	0.95		0.95
33 (dopa 34 (nore 35 Trypt 36 (sero	Homovanillic (HVA) amine) VanillyImandelic (VMA) pinephrine, epinephrine) HVA / VMA Ratio tophan Metabolites 5-Hydroxyindoleacetic (5-HIAA tonin)	0.32 - 1.4 s) ≤ 2.9	0.95	Ø.10	(1.95)
33 (dopa 34 (nore 35 Trypt	Homovanillic (HVA) nmine) VanillyImandelic (VMA) pinephrine, epinephrine) HVA / VMA Ratio tophan Metabolites 5-Hydroxyindoleacetic (5-HIAA	0.32 - 1.4	0.95		1 95

Requisition							Physician:	IN COMMON LABORATORIES
Patient Name: Alex Tigchelaar 36016279							Date of Collection:	10/3/2016
letabolio	c Markers in Urine	Reference Ra (mmol/mol creat				atient alue	Reference Po	opulation - Males Age 13 and Over
Pyrimi	idine Metabolites -	Folate Metabolis	sm					
40 Ura	acil		≤	6.9		5.0		5.0
I1 Th	ymine		≤	0.36		0.11	Q.11	<u> </u>
Keton	e and Fatty Acid Ox	cidation						
0 01	Ladaca da Karta			4.0		0.00		
	Hydroxybutyric etoacetic		≤ <	1.9		0.23	(0.23)	
	etoacetic lydroxybutyric		<u>^</u>	4.3		0.18	0.18	
	nylmalonic	0.13	_	2.7		0.57	0.57	
	thylsuccinic		≤	2.3		0.89		(89)
	ipic		≤	2.9		0.22	0.22	
8 Su	beric		≤	1.9		0.78		0.78
9 Se	bacic		≤	0.14		0	0.00	
Nutriti	onal Markers							
itamin B 0 Me	12 thylmalonic *		<	2.3		0.38	Q.38	
tamin B			_	2.0		0.00	V.30	
	ridoxic (B6)		≤	26		0	0.00	
itamin B 2 Pa	5 ntothenic (B5)		≤	5.4		0.78	0.78	
	2 (Riboflavin)							
3 Glu	utaric *		≤	0.43		0.09	0.09	
tamin C 4 As	corbic	10	-	200	L	0	0.00	
	10 (CoQ10) Hydroxy-3-methylglutari	c *	≤	26		5.8	5.8	
	ne Precursor and Chela Acetylcysteine (NAC)	ting Agent	≤	0.13		0	0.00	
	tamin H) httylcitric #	0.15	-	1.7		0.22	0.22	

A high value for this marker may indicate a deficiency of this vitamin.

463629 Physician: IN COMMON LABORATORIES Requisition #: 10/3/2016 Patient Name: Alex Tigchelaar 36016279 Date of Collection: **Patient Metabolic Markers in Urine Reference Range** Reference Population - Males Age 13 and Over (mmol/mol creatinine) Value **Indicators of Detoxification** Glutathione **5**8 Pyroglutamic * 5.7 25 9.5 2-Hydroxybutyric * 0.32 59 ≤ 1.2 (0.32) **Ammonia Excess Orotic** 0.10 ≤ 0.46 0.10 Aspartame, salicylates, or GI bacteria

0.32

≤ 0.86

* A high value for this marker may indicate a Glutathione deficiency.

Amino Acid Metabolites

2-Hydroxyhippuric

62	2-Hydroxyisovaleric		≤	0.41	0	0.00
63	2-Oxoisovaleric		≤	1.5	0.11	(0.1)
64	3-Methyl-2-oxovaleric		≤	0.56	0.06	0.06
65	2-Hydroxyisocaproic		≤	0.39	0.04	0.04>
66	2-Oxoisocaproic		≤	0.34	0.07	(1.0)
67	2-Oxo-4-methiolbutyric		≤	0.14	0.02	0.00
68	Mandelic		≤	0.09	0.05	(05)
69	Phenyllactic		≤	0.10	0.01	0.0
70	Phenylpyruvic	0.02	-	1.4	0.30	0.30
71	Homogentisic		≤	0.23	0	0.00
72	4-Hydroxyphenyllactic		≤	0.62	0.09	0.03
73	N-Acetylaspartic		≤	2.5	0	0.00
74	Malonic		≤	9.9	2.2	2.2

Mineral Metabolism

75 Phosphoric 1 000 - 4 900 1 321

0.32

Requisition #: 463629 Physician: IN COMMON LABORATORIES

Patient Name: Alex Tigchelaar 36016279 Date of Collection: 10/3/2016

Indicator of Fluid Intake

76 *Creatinine 270 mg/dL

*The creatinine test is performed to adjust metabolic marker results for differences in fluid intake. Urinary creatinine has limited diagnostic value due to variability as a result of recent fluid intake. Samples are rejected if creatinine is below 20 mg/dL unless the client requests results knowing of our rejection criteria.

Explanation of Report Format

The reference ranges for organic acids were established using samples collected from typical individuals of all ages with no known physiological or psychological disorders. The ranges were determined by calculating the mean and standard deviation (SD) and are defined as ± 2SD of the mean. Reference ranges are age and gender specific, consisting of Male Adult (≥13 years), Female Adult (≥13 years), Male Child (<13 years), and Female Child (<13 years).


There are <u>two</u> types of graphical representations of patient values found in the new report format of both the standard Organic Acids Test and the Microbial Organic Acids Test.

The first graph will occur when the value of the patient is within the reference (normal) range, defined as the mean plus or minus two standard deviations.


The second graph will occur when the value of the patient exceeds the upper limit of normal. In such cases, the graphical reference range is "shrunk" so that the degree of abnormality can be appreciated at a glance. In this case, the lower limits of normal are not shown, only the upper limit of normal is shown.

In both cases, the value of the patient is given to the left of the graph and is repeated on the graph inside a diamond. If the value is within the normal range, the diamond will be outlined in black. If the value is high or low, the diamond will be outlined in red.

Example of Value Within Reference Range



Example of Elevated Value



Requisition #:

463629

Physician:

IN COMMON LABORATORIES


Patient Name:

Alex Tigchelaar 36016279

Date of Collection:

10/3/2016

Neurotransmitter Metabolism Markers



The diagram contains the patient's test results for neurotransmitter metabolites and shows their relationship with key biochemical pathways within the axon terminal of nerve cells. The effect of microbial byproducts on the blockage of the conversion of dopamine to norepinephrine is also indicated.

Requisition #: 463629 Physician: IN COMMON LABORATORIES

Patient Name: Alex Tigchelaar 36016279 Date of Collection: 10/3/2016

Interpretation

HVA levels below the mean (Marker 33) may indicate lower production of the neurotransmitter dopamine, perhaps due to low dietary intake of the amino acid precursors phenylalanine or tyrosine. Homovanillic acid is a metabolite of the neurotransmitter dopamine. Supplementation with phenylalanine or tyrosine may be beneficial. Enzyme cofactors magnesium, B6 (pyridoxine) or biopterin may also be deficient; neurotransmitter levels may increase with supplementation with these cofactors if these are deficient.

VMA levels below the mean (Marker 34) may indicate lower production of the neurotransmitter norepinephrine or the hormone adrenaline, perhaps due to low dietary intake of the amino acid precursors phenylalanine or tyrosine. Vanylmandelic acid (VMA) is a metabolite of norepinephrine or adrenaline. Low VMA may also result from blocked conversion of dopamine to norepinephrine by Clostridia metabolites. Supplementation with phenylalanine or tyrosine may be beneficial. Enzyme cofactors magnesium, B6 (pyridoxine) or biopterin may also be deficient and respond to supplementation.

5-hydroxyindoleacetic acid (5-HIAA) levels below the mean (Marker 36) may indicate lower production of the neurotransmitter serotonin. 5-hydroxy-indoleacetic acid is a metabolite of serotonin. Low values have been correlated with symptoms of depression. Supplementation with the precursor 5-HTP (5-hydroxytryptophan) at 50-300 mg/day may be beneficial. Supplementation with tryptophan itself may form the neurotoxic metabolite quinolinic acid, however, 5-HTP is not metabolized to quinolinic acid. Excessive tryptophan supplementation has been associated with eosinophilia myalgia syndrome.

High quinolinic acid / 5-HIAA ratio (Marker 39) indicates an imbalance of these organic acids and may be a sign of neural excitotoxicity. Quinolinic acid is an excitotoxic stimulant of certain brain cells that have NMDA-type receptors. Overstimulated nerve cells may die. Brain toxicity due to quinolinic acid has been implicated in Alzheimer's disease, autism, Huntington's disease, stroke, dementia of old age, depression, HIV-associated dementia, and schizophrenia. However, quinolinic acid is derived from the amino acid tryptophan and is an important intermediate that the body uses to make the essential nutritional cofactor nicotinamide adenine dinucleotide (NAD), which can also be derived from niacin (B3).

An elevated ratio is not specific for a particular medical condition and is commonly associated with excessive inflammation due to recurrent infections. If quinolinic acid is not elevated, low 5-HIAA from serotonin may be the source of the imbalance. Supplementation with 5-HTP may increase serotonin levels, but 5-HTP is not metabolized to quinolinic acid. Immune overstimulation, excess adrenal production of cortisol due to stress, or high exposure to phthalates may also increase the quinolinic acid/5-HIAA acid ratio.

The drug deprenyl or the dietary supplements carnitine, melatonin, capsaicin, turmeric (curcumin) and garlic may reduce brain damage caused by quinolinic acid. Niacin (nicotinic acid) and niacinamide may also reduce quinolinic acid production by decreasing tryptophan shunting to the quinolinic acid pathway. Inositol hexaniacinate as an adult dose of 500-1000 mg does not cause niacin flush.

Pyridoxic acid (B6) levels below the mean (Marker 51) may be associated with less than optimum health conditions (low intake, malabsorption, or dysbiosis). Supplementation with B6 (20 - 50 mg/day) or a multivitamin may be beneficial.

Pantothenic acid (B5) levels below the mean (Marker 52) may be associated with less than optimum health conditions. Supplementation with B5 (250 mg/day) or a multivitamin may be beneficial.

Ascorbic acid (vitamin C) levels below the mean (Marker 54) may indicate a less than optimum level of the antioxidant vitamin C. Suggested supplementation is 1000 mg/day of buffered vitamin C, divided into 2-3 doses.

Requisition #: 463629 Physician: IN COMMON LABORATORIES

Patient Name: Alex Tigchelaar 36016279 Date of Collection: 10/3/2016

Low citramalic, 2-hydroxyphenylacetic, 4-hydroxyphenylacetic, 4-hydroxyphenzoic, 4-hydroxyhippuric, 3-indoleacetic, glyceric, glycolic, oxalic, lactic, pyruvic, 2-hydroxybutyric, fumaric, malic, aconitic, quinolinic, kynurenic, quinolinic/5-HIAA ratio, thymine, ethylmalonic, methylsuccinic, adipic, suberic, glutaric, 3-hydroxy-3-methylglutaric, methylcitric, or orotic values have no known clinical significance.

Low values for amino acid metabolites (Markers 62-74) indicate the absence of genetic disorders of amino acid metabolism. These markers are deamination (ammonia removed) byproducts that are very elevated only when a key enzyme has low activity; slight elevations may indicate a genetic variation or heterozygous condition which may be mitigated with diet or supplementation. Low values are not associated with inadequate protein intake and have not been proven to indicate specific amino acid deficiencies.

High quality nutritional supplements can be purchased through your practitioner or at New Beginnings Nutritionals, www.NBNUS.com or call 877-575-2467.